NEW YORK, April 12, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Rasna Therapeutics, Inc. (OTCQX: RASP), a clinical-stage biotechnology company focused on delivering novel therapeutics and biomarkers for acute myeloid leukemia (AML) patients, has qualified to trade on the OTCQX® Best Market. Rasna Therapeutics upgraded to OTCQX from the OTCQB® Venture Market.
Rasna Therapeutics begins trading today on OTCQX under the symbol "RASP." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Congratulations to Rasna Therapeutics on upgrading to the OTCQX market from OTCQB," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "OTCQX companies meet high financial standards, follow corporate governance best practices and are distinguished by the integrity of their operations. We look forward to supporting Rasna Therapeutics and its shareholders."
"The uplisting of Rasna Therapeutics to OTCQX is an important stepping stone on our development path," commented Alessandro Padova, Chairman of Rasna Therapeutics. "As we look to expand our portfolio of therapeutics under development, our entry into a more liquid market should provide the benefits of access to a broader pool of capital and greater visibility within the financial community."
Rasna Therapeutics was sponsored for OTCQX by Sheppard, Mullin, Richter & Hampton LLP, a qualified 3rd party firm responsible for providing guidance on OTCQX requirements and recommending membership.
Rasna Therapeutics, Inc. is a biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna's primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. The company has a balanced portfolio with clinical programs targeting three druggable intervention points with potential to improve safety and efficacy of current AML combination therapies, around which it has robust IP and substantial freedom to operate: RASP-101, an established anticancer therapeutic for treating nucleophosmin (NPM1) mutated acute myeloid leukemia (AML); RASP-201, an inhibitor of lysine specific histone demethylase 1 (LSD1 or KDM1A), which is overexpressed in several human cancers including AML and plays an important role in epigenetic modification that contributes to cellular proliferation; and, RASP-301, an high affinity NPM1 binding molecules exhibiting selective cytotoxic activity on AML cells.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-rasna-therapeutics-to-otcqx-300438154.html
SOURCE OTC Markets Group Inc.